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In this issue of Critical Care, Fernández-Serrano and 
colleagues [1] evaluate the eﬃ   cacy of corticosteroids in 
the treatment of hospitalized patients with severe 
community-acquired pneumonia (CAP). Severe CAP is a 
major cause of admission to intensive care units (ICUs) 
and, despite optimal antibiotic and supportive treatment, 
remains associated with exceedingly high mortality rates 
[2]. For this legitimate reason, intensivists have worked 
for decades in numerous clinical trials aiming to identify 
adjunctive strategies for this condition. In this sense, 
corticosteroids are the prototypical ‘ideal candidate’. 
Corticosteroids present anti-inﬂ  ammatory  properties 
that may reduce the intense proinﬂ  ammatory cytokine 
response and thus modify the occurrence and severity of 
organ failures [3]. Also, corticosteroids are easily ad-
minis  trated and relatively inexpensive and, clinicians 
believe, do no harm. Given this long list of favorable 
attributes and the positive results from a multicenter 
randomized controlled trial (RCT) [4], it is fair of us 
physicians to want corticosteroids to ﬁ  ll the role of ‘the 
ideal adjunctive sepsis therapy’.
In 1958, the Canadian-American economist John 
Kenneth Galbraith coined the expression ‘conventional 
wisdom’. Th  e term was employed to describe concepts 
that are generally accepted as true without being 
questioned. Although such ideas are widely held, further 
examination based on solid evidence proves them to be 
wrong. Th  is may apply to what happened to cortico-
steroids in sepsis in the last decade.
Physicians encouraged by available evidence and con-
ventional wisdom prescribed steroids in up to 80% of 
patients with severe sepsis and septic shock [5]. Th  e 
reliance on corticosteroids as the best choice was so 
strong that it reduced the patient inclusion rate in the 
Corticus Study and potentially made the study biased for 
including only patients who, their physicians believed, 
would not require steroids [6]. Th  e willingness to 
prescribe corticosteroids is disproportionately elevated 
given the available evidence.
In patients with severe sepsis, clinical trials [6], well-
designed observational studies [7], and data from an 
international registry [5] could not demonstrate a reduced 
need for vasopressors or an improvement in organ 
dysfunctions or survival. In regard to severe CAP, a 
systematic review performed in 2008 had already pointed 
out that the available studies do not support the recom-
mendation of corticosteroids as a standard of care [8]. 
Subsequent observational data [9] and an RCT [10] also 
failed to show any signiﬁ  cant clinical beneﬁ  t associated 
with corticosteroid administration for this subgroup of 
patients, irrespective of disease severity.
Fernández-Serrano and colleagues [1] present the 
results of a small (n = 45) single-center RCT evaluating 
the potential beneﬁ  t of a methylprednisolone (MPRD) 
regimen on outcomes of non-ICU CAP patients, namely 
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© 2011 BioMed Central Ltdthe need for invasive or non-invasive mechanical venti  la-
tion. MPRD was found to be associated with a faster 
clinical, radiological, and laboratory resolution of CAP, 
but with similar mortality. Th   e issue of small sample size 
notwithstanding, ﬁ  ve patients (22.7%) from the placebo 
group needed ICU admission and three required invasive 
mechanical ventilation, whereas only one from the 
MPRD arm was admitted to the ICU for non-invasive 
ventilation, and this resulted in a marked asymmetry 
between the two groups. Despite these caveats, the 
authors were able to conclude that MPRD had a positive 
impact on the clinical course of these very select CAP 
patients. In our opinion, the results are hard to translate 
into daily practice because of patient selection and small 
sample size and should be viewed with a measure of 
caution.
In view of the current evidence, what is the future of 
corticosteroids in severe CAP? Is there clinical equipoise 
to justify new clinical trials in this topic? Given the 
current studies, it can be said that, although there is 
insuﬃ   cient evidence to support corticosteroid use as the 
standard of care in severe CAP, it is still an unresolved 
matter that deserves further investigation. Future trials 
should learn from previously published studies to over-
come their limitations. Th  is does not mean that we 
should repeat previous studies with larger sample sizes. 
Instead, we must work on better study designs that make 
use of a reliable surrogate of outcomes and that represent 
a true advance in the reﬁ   nement of patient selection. 
Unlike in the examples of severe sepsis and CAP, better 
patient selection may lead to signiﬁ  cant clinical beneﬁ  ts 
for subgroups of patients with severe infections treated 
with adjunctive corticosteroids. Beneﬁ   ts of systemic 
cortico  steroids in septic patients were demonstrated only 
in well-deﬁ  ned infections such as bacterial meningitis in 
immunocompetent hosts [11] and Pneumocystis jirovecci 
pneumonia in HIV patients [12]. Nonetheless, despite new 
scoring systems [13] and biomarkers, these tools are not 
validated as surrogates of response to corticosteroids [14].
In conclusion, we believe that, while corticosteroids 
should not be routinely employed as adjuvant therapy for 
severe CAP, there is suﬃ     cient equipoise to continue 
studying the use of corticosteroids. Th  is is still an open 
ﬁ  eld that may signiﬁ  cantly evolve by applying the concept 
of theragnostics for severe CAP.
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